Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8539519 | 0.89 | GABRA1 (0.50) | GABRA1GABRB2PNMTTAAR1SLC6A2 | |
| SCHEMBL2141223 | 0.85 | PNMT (0.60) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL2141228 | 0.85 | PNMT (0.60) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL5259036 | 0.85 | PNMT (0.60) | PNMTTAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL1653015 | 0.83 | GABRA1 (0.44) | GABRA1GABRB2PNMTTRPA1TAAR1 | |
| SCHEMBL9338131 | 0.83 | TDP1 (0.46) | GABRA1GABRB2PNMTTRPA1TAAR1 | |
| SCHEMBL16960175 | 0.81 | GABRA1 (0.43) | GABRA1GABRB2TSHR | |
| SCHEMBL19567243 | 0.81 | PRKCI (0.54) | PRKCI | |
| Phosphoric Acid SCHEMBL29099239 | 0.81 | GABRA1 (0.46) | GABRA1GABRB2PNMT | |
| Phosphoric Acid SCHEMBL28056683 | 0.81 | GABRA1 (0.46) | GABRA1GABRB2PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-116903494-A | Preparation method of alpha-alkyl nitrile derivative and alpha-alkenyl nitrile derivative | 浙江工业大学 | 2023-10-20 | — | — | CN | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | GENZYME CORPORATION (US) | 2015-05-07 | — | — | US | disclosed |
| US-8921547-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-8637557-B2 | Aminothiazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-01-28 | — | — | US | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6271248-B1 | USED IN TREATING HYPERTENSION, PULMONARY HYPERTENSION, RENAL/ GLOMERULAR/MESANGIAL CELL DISORDERS, ENDOTOXEMIA, ISCHEMIA, TUMOR GROWTH, ATHERSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, PROSTATIC HYPERTROPHY, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| US-6080774-A | Substituted biphenylsulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0768305-A1 | N-Isoxazolyl-biphenylsulfonamide derivatives, their preparation and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5149884-A | Oxidative dehydrogenation of aromatic or aliphatic alcohols in gas phase | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-22 | — | — | US | disclosed |
| EP-0244632-B1 | TUBE BUNDLE REACTOR, ITS USE IN EXOTHERMAL ORGANIC REACTIONS AND PROCESS FOR THE PREPARATION OF KETONES AND ALDEHYDES | BASF Aktiengesellschaft (DE) | 1991-02-20 | — | — | EP | disclosed |
| US-4224254-A | OXIDATION OF AROMATIC ALCOHOLS, SILVER CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1980-09-23 | — | — | US | disclosed |
| EP-0004881-A2 | Process for the preparation of aromatic and araliphatic aldehydes | BASF Aktiengesellschaft (DE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126512-A1 | Modulators Of TNF-Alpha Signaling | TNF, TNFRSF1A, TNFRSF9 | GABRA1 1264/4885GABRB2 1057/4885ENPP2 93/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | GABRA1 486/4885GABRB2 738/4885ENPP2 918/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | GABRA1 3423/4885GABRB2 3822/4885ENPP2 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.